



HAL
open science

Adverse Drug Reaction-Related to Drug Shortage: A Retrospective Study on the French National Pharmacovigilance Database

Delphine Bourneau-Martin, Marina Babin, Aurelie Grandvullemin, Charlotte Mullet, Francesco Salvo, Allison Singier, Morgane Cellier, Audrey Fresse, Claire de Canecaude, Tessa Pietri, et al.

► To cite this version:

Delphine Bourneau-Martin, Marina Babin, Aurelie Grandvullemin, Charlotte Mullet, Francesco Salvo, et al.. Adverse Drug Reaction-Related to Drug Shortage: A Retrospective Study on the French National Pharmacovigilance Database. *British Journal of Clinical Pharmacology*, 2023, 89 (3), pp.1080-1088. 10.1111/bcp.15550 . hal-03834969

HAL Id: hal-03834969

<https://hal.science/hal-03834969v1>

Submitted on 31 Oct 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.






L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

ORIGINAL ARTICLE

Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database

Delphine Bourneau-Martin¹ | Marina Babin¹ | Aurélie Grandvullemin²  |
 Charlotte Mullet¹ | Francesco Salvo^{3,4}  | Allison Singier³ | Morgane Cellier¹ |
 Audrey Fresse⁵  | Claire de Cancaude⁶ | Tessa Pietri⁷ | Guillaume Drablier¹ |
 Hélène Geniaux⁸ | Laurence Lagarce¹ | Marie-Laure Laroche^{8,9}  |
 Marie Briet^{1,10,11}  | On behalf of the French Network of Regional Pharmacovigilance Centres

¹Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, Angers, France

²Centre Régional de Pharmacovigilance de Dijon, CHU Dijon Bourgogne, Dijon, France

³Univ. Bordeaux, INSERM, BPH, U1219, Bordeaux, France

⁴Service de Pharmacologie, CHU de Bordeaux, Bordeaux, France

⁵CHRU de Nancy - Hôpitaux de Brabois, Centre Régional de Pharmacovigilance, Vandœuvre-lès-Nancy, France

⁶Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur Le Médicament, Faculté de Médecine, Centre Hospitalier Universitaire, Faculté de Médecine, Toulouse, France

⁷Aix-Marseille Université, Inserm, UMR 1106, Assistance publique - Hôpitaux de Marseille, Service de pharmacologie clinique, Centre régional de pharmacovigilance, Marseille, France

⁸Regional Pharmacovigilance Centre of Limoges, Department of Pharmacology-Toxicology and Pharmacovigilance, CHU Limoges, Limoges, France

⁹UR 24134 (Vie Santé: Vieillesse, Fragilité, Prévention, e-Santé), IFR OMEGA HEALTH, Université de Limoges, Limoges, France

¹⁰Université d'Angers, Angers, France

¹¹MitoVasc Research Institute, UMR CNRS 6214 INSERM 1083, Angers, France

Correspondence

Marie Briet, Department of Pharmacology-Toxicology and Pharmacovigilance, University Hospital of Angers, 4 rue Larrey, Angers 49100, France.

Email: marie.briet@chu-angers.fr

Funding information

CHU Angers, Grant/Award Number: AOI 2020

Aim: Drug shortages are a growing global health issue. The aim of the study was to evaluate the consequences of drug shortages on patient safety based on data recorded in the French National Pharmacovigilance Database.

Methods: All cases involving drug shortages reported from 1985 to the end of 2019 were extracted from the database.

Results: Following the selection process, 462 cases were included. The number of cases increased significantly from 2004 to 2019. Cases mainly involved drugs from the nervous system (22.1%, 95% confidence interval [CI] 17.5–27.0%), the cardiovascular system (16.4%, 95% CI 11.9–21.4%) and anti-infectives for systemic use (14.3%, 95% CI 9.7–19.2%) ATC classes. Most of the cases reported an adverse drug

The authors confirm that the principal investigator for this study is Prof. Marie Briet.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *British Journal of Clinical Pharmacology* published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.

reaction (ADR) belonging to the SOC nervous system (21%, 95% CI 18–24%), skin and subcutaneous (14%, 95% CI 11–17%), general (13%, 95% CI 10–17%) and gastrointestinal (8%, 95% CI 5–11%) disorders. Disease worsening was observed in 15.9% of the cases, mostly related to a lack of efficacy of the replacement drug. Half of the cases were considered as serious. Evolution was favourable in 79.4% of the cases. Death and/or life-threatening situations were reported in 5.8% of the cases. Medication errors (MEs) were identified in 51 cases (11%), mostly occurring at the administration step and involving a human factor.

Conclusion: This study emphasizes the clinical impact of drug shortage in terms of ADRs, ME and inefficiency. These observations underline the importance of a global health policy programme to limit the occurrence of drug shortages and to reinforce the information provided to patients and health care professionals in this context to limit risk.

KEYWORDS

adverse drug reaction, drug shortage, medication error, pharmacovigilance

1 | INTRODUCTION

Drug shortages are a recurrent public health issue that affects all health care organizations worldwide. The first reports were published in the early 1970s.¹ Drug shortage became a daily concern for health care professionals and national and international health authorities in the 2000s and has been a growing issue ever since. Many factors are involved in this phenomenon including the growing dependence on raw ingredients manufactured abroad, the issue of low-profit drugs in business strategy, the increased regulatory requirements and quality controls that rule out more and more drugs during production circuits and increasing demand.²

Communications about drug shortages are usually associated with position statements from health organizations that recommend identifying therapeutic alternatives or establish rules for patient prioritization. Drug shortage increases the demands on health care staff, as extra time must be spent prescribing and dispensing drugs as a result.³ For patients, drug shortage usually leads to changes in medications and/or involuntary discontinuation that may compromise their safety due to a lack of efficacy or the occurrence of a medication error and/or an adverse drug reaction (ADR). In the literature, cases of ADRs and medication errors have been reported in the context of drug shortage involving anti-cancer drugs,^{4,5} anaesthetic products^{6–8} and anti-infective drugs.⁹

The present study aimed to provide an overview of ADRs, medication errors and inefficiency occurring in the context of drug shortage based on the reports collected in the French National Pharmacovigilance Database.

2 | METHODS

2.1 | Data source

This study was conducted on the French Pharmacovigilance Database (FPVB). The FPVB centralized reports of suspected ADR notified to

What is already known about this subject

- Drug shortage is a growing global health issue.
- Drug shortage usually leads to changes in medications and/or involuntary discontinuation that can compromise patient safety.
- The aim of this study was to evaluate patient safety in the context of drug shortages based on pharmacovigilance data.

What this study adds

- The number of pharmacovigilance notifications related to drug shortages increased over time and significantly faster than the total number of notifications in the French pharmacovigilance database.
- Almost all pharmacological classes were involved. Half of the cases were considered as serious.
- Drug replacement resulted in medication errors in 11% of the cases, which were mainly represented by dosage errors.

the 31 regional pharmacovigilance centres in France. ADR cases are reported by health care professionals and patients to these centres. ADR reports are documented and analysed by pharmacovigilance professionals to evaluate drug accountability and then entered in the FPVB. Data recorded include patient characteristics, medical history, time to onset, drugs taken by the patients and adverse effects recorded using the Medical Dictionary for Regulatory Activities

(MedDRA®) classification. At the time of data extraction, 801 373 reports of suspected ADRs had been submitted to the FPVB.

2.2 | Data selection and analysis

The first step in selecting ADR reports used the following terms as inclusion criteria: *stock* (stock), *penurie* (shortage), *approvisionnement* (supply) and *retrait lot* (batch withdrawal) in the commentary from 1985 to 31 December 2019. The medical and pharmacological comments of the selected reports were reviewed by a pharmacovigilance expert to select only reports related to ADRs, inefficiency or medication errors in the context of drug shortage.

The following data were selected for all cases: age, sex, shortage drugs, drug start date, drug indication, replacement drug, ADR, report date and ADR date, expectedness, seriousness, ADR evolution and medication error. Time to onset of suspected ADR was calculated using drug start date and first date of reported ADR. The expected nature of the adverse effect was indicated when the adverse effect was written in the summary of product characteristics (SmPC) of the suspected drug. Drugs were classified following the Anatomical Therapeutic Chemical (ATC) classification in which the active substances are divided into different groups according to the organ or system on which they act and their therapeutic, pharmacological and chemical properties.

Descriptive analysis was performed. Numbers and percentages were calculated for qualitative variables. We determined the percentages and their confidence intervals using the exact Clopper-Pearson method for a binomial proportion with the R package PropCIs and the Sison-Glaz method for a multinomial proportion with the R package DescTools (R Studio® version 1.3.1093 for Windows®, version R 4.0.3). The mean and standard deviation or median and range were calculated for quantitative variables. To investigate whether the increase in drug shortage-related cases is linked to the increase of FPVB cases, a two-tailed Mann-Kendall trend test was applied to the rate of drug shortage-related cases per 10 000 cases in the FPVB. This test was performed for the 2004–2019 period on data with more than five drug shortage-related cases a year.

3 | RESULTS

3.1 | Description of the cases studied

A total of 1895 cases were identified following the first selection step using predefined keywords. After exclusion of 243 cases from pharmaceutical laboratories, 34 duplicate cases and 1156 cases where the situations described did not correspond to a drug shortage, 462 cases reporting 726 ADRs were included in the study (Figure S1). The first case was reported in 1995. The number of reported cases increased over time, particularly from 2010 to 2019. The highest number of cases was reported in 2019 (Figure 1A). Between 2004 and 2019, the




FIGURE 1 Increased number of notifications related to drug shortage in the French National Pharmacovigilance Database since 2004 (first year with more than five cases per year). (A) Number of reported drug shortage-related cases from 2004 to 2019. (B) Number of reported drug shortage-related cases per French Pharmacovigilance Database 10 000 cases from 2004 to 2019

increase in drug shortage-related cases was greater than the increase in FPVB total cases (two-tailed Mann-Kendall trend test; $P = .006$; Figure 1B).

The large majority of the reports were provided by health care professionals (92.2%). The cases mostly involved adult patients with a median age of 61 years and a marginal majority of women (51.5%). Drugs in shortage were replaced in almost all cases (95.7%), mainly by a drug from the same ATC class (93.0%). A different active principle between the drug in shortage and the replacement drug was found in 41.2% of the cases (Table 1). Most of the cases were related to ADRs (84.0%), 28.3% of which were unexpected according to the SmPCs. The majority of the reported ADRs were related to the replacement drug (86.4%). Disease worsening was observed in 15.9% of the cases, which was mostly due to a lack of efficacy of the replacement drug. The outcome was reported as recovered in 79.4% of the cases. Serious ADRs were observed in 46% of the cases. The reported ADRs belonged mainly to the MedDRA System Organ Classes (SOC) ‘nervous system disorders’ (21%, 95% CI 18–24%), ‘skin and subcutaneous disorders’ (14%, 95% CI 11–17%), ‘general disorders and administration site conditions’ (13%, 95% CI 10–17%) and ‘gastrointestinal disorders’ (8%, 95% CI 5–11%) (Figure 2).

TABLE 1 Characteristics of cases of adverse drug reactions occurring in a context of drug shortage, 1985–2019, French National Pharmacovigilance Database (462 cases, 726 adverse reactions)

Parameters	n	%	CI _{low}	CI _{high}
Median age in years (min–max)	61 (0.04–95)			
Child (0–15)	34	7.3	2.6	12.2
Adult (16–64)	224	48.5	43.7	53.3
Older adult (>65)	194	42.0	37.2	46.8
Unknown	10	2.2	0.0	7.0
Sex (n, %)				
Male	221	47.8	43.3	52.7
Female	238	51.5	47.0	56.4
Unknown	3	0.7	0.0	5.6
Reporter qualification (n, %)				
Health care professional	426	92.2	89.4	94.4
Patient	36	7.8	5.5	10.6
Community vs. hospital reporter (n, %)				
Hospital	291	63.0	58.4	67.4
Outpatient	171	37.0	32.6	41.2
Type of case (n, %)				
Adverse drug reaction	388	84	80.9	87.2
Medication error without adverse drug reaction	10	2.16%	0.0	5.3
Medication error with adverse drug reaction	41	8.9	5.8	12.1
Withdrawal	10	2.16	0.0	5.3
Overdose	5	1.08	0.0	4.3
Interaction	6	1.3	0.0	4.5
Others	2	0.4	0.0	3.6
Seriousness (n, %)	214	46.3	41.7	51.0
Hospitalization or prolongation of hospitalization	97	21.0	16.5	25.8
Medically significant situation	90	19.5	14.9	24.3
Life-threatening situation	18	3.9	0.0	8.7
Death	9	1.9	0.0	6.8
Outcome of the cases (n, %)				
Recovered	367	79.4	76.0	83.0
Recovered with sequelae	2	0.4	0.0	4.0
Death	9	1.9	0.0	5.5
Not recovered/unresolved	54	11.7	8.2	15.2
Unknown	30	6.5	3.0	10.0
Expected/unexpected nature of adverse drug reaction (n, %)				
Expected	320	69.3	65.1	73.6
Unexpected	129	28.3	23.8	32.3
Not applicable	13	2.4	0.0	7.2
Worsening of the disease (n, %)	69	15.9	11.8	18.5
Due to the inefficiency of the replacement drug	58	12.6	9.5	15.7
Due to the absence of replacement drug	11	2.4	0.0	5.5
No impact	393	85.1	82.0	88.2
Medication error (n, %)	51	11.0	8.3	14.3
Drug replacement				
Replacement of the drug in shortage (n, %)	442	95.7	93.4	97.3

TABLE 1 (Continued)


Parameters	n	%	CI _{low}	CI _{high}
ATC classes of the replacement drug				
Same as the drug in shortage	411	93.0 ^a	90.2	95.2
Same active principle	229	51.8 ^a	47.0	56.8
Different active principle	182	41.2 ^a	36.4	46.2
Different than the drug in shortage	31	7.0 ^a	4.8	9.8
Ineffectiveness of the replacement drug ^b (n, %)	67	15.2 ^a	11.9	18.8
ADR related to the replacement drug (n, %)	382	86.4 ^a	82.9	89.5

Abbreviations: ADR, adverse drug reaction; ATC, anatomical therapeutic chemical; CI, 95% confidence interval.

^aPercentages were calculated based on a total of 442 cases in which the drugs in shortage were replaced.

^bCases with or without disease aggravation.

FIGURE 2 Number of reported cases according to the System Organ Class



3.2 | Medication errors in the context of drug shortage

Medication errors occurring in a context of drug shortage were reported in 51 cases (Tables 2 and S1). The majority of the medication errors occurred at the drug administration step (67%) and mostly involved dosing errors. Human factors were the main reported cause of the error (88%). Packaging or design problems were involved in 22% of the medication error cases (Table 2). Table S2 shows the drugs in shortage and replacement drugs involved as well as the step, nature, cause of medication error and seriousness.

The drug in shortage was replaced in all cases. In a large majority of the cases (94%), this was replaced by a drug from the same class and by one with the same active principle in 66% of the cases. Medication errors were associated with the occurrence of an ADR in 80.4% of the cases, half of which were considered as serious. The outcome was favourable in 68.6% of the cases. Life-threatening situations were reported in three cases (6.0%) and fatal outcome in four cases (7.8%) of the medication error cases (Table S1).

3.3 | Description of the drug shortage cases

The drugs in shortage reported in the 462 cases are presented in Table S3 and Figure 3. The ATC classes that were most highly represented were the nervous system ($n = 102$, 22.1%, 95% CI 17.5–27.0%) mainly represented by antiepileptics ($n = 49$, 48.0%, 95% CI 38.0–58.1%), the cardiovascular system ($n = 76$, 16.4%, 95% CI 11.9–21.4%) mainly represented by agents acting on the renin angiotensin system ($n = 32$, 42.1%, 95% CI 30.9–54.0%) and anti-infectives for systemic use ($n = 66$, 14.3%, 95% CI 9.7–19.2%) mainly represented by immune sera and immunoglobulins ($n = 32$, 48.5%, 95% CI 36.0–61.1%).

Table S4 describes the drug classes (selected using ATC classification level 3) involved in more than 15 cases and the related ADRs.

Forty-nine cases involved antiepileptics, mainly valproic acid and its derivatives and phenytoin. Toxicity of the replacement drug was observed in 59% of the cases, mainly represented by neurological disorders. Inefficiency of the replacement drug was observed in one third of these cases.

TABLE 2 Step, nature and cause of medication error occurring in the context of drug shortage, 1985–2019, French National Pharmacovigilance Database ($n = 51$)

Parameters	<i>n</i>	%
Medication error step		
Administration	34	66.7
Dispensation	7	13.7
Preparation	6	11.8
Prescription	4	7.8
Nature of the medication error^a		
Dose error	29	56.8
Drug error	9	17.6
Administration time error	5	9.8
Administration technique error	3	5.9
Error in the route of administration	3	5.9
Galenic form error	2	3.9
Therapeutic and clinical monitoring error	1	2.0
Expired, spoiled or poorly preserved medication	1	2.0
Cause of error^a		
Human factors	45	88.2
Packaging or design problems	11	21.5
Labelling and/or information problems	7	13.7

^aSeveral causes and natures of error are possible for one case.




FIGURE 3 Numbers of drug shortage cases classified according to Anatomical Therapeutic Chemical classes (level 1), 1985–2019, French Pharmacovigilance database. A, alimentary tract and metabolism; B, blood and blood-forming organs; C, cardiovascular systems; D, dermatologicals; G, genito-urinary system and sex; H, systemic hormonal preparations, excl. sex hormones and insulins; J, anti-infectives for systemic use; L, antineoplastic agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products, insecticides and repellents; R, respiratory system; S, sensory organs; V, various

Thirty-eight cases involved a shortage of antihistamines, largely represented by a shortage of intravenously administered dexchlorpheniramine ($n = 36$). In all cases except one, dexchlorpheniramine was replaced by promethazine, resulting in neurological disorders and

anticholinergic syndrome. Inefficiency of the alternative drug was observed in two cases.

Twenty-six cases involved antithrombotic drugs with a majority of haemorrhagic or thrombotic disorders. Inefficiency of the replacement drug was reported in almost one third of the cases.

Thirty-two cases involved drugs acting on the renin-angiotensin system with a large majority of valsartan shortage cases ($n = 25$). Various reactions were reported including hypotension or hypertension, gastro-intestinal disorders such as lymphocytic colitis among others detailed in Table S4. Inefficiency of the replacement drug was reported in 22% of the cases.

Thirty-two cases involved immune sera or immunoglobulins and were mainly related to infusion reactions. Inefficiency of the replacement drug was reported in 16% of the cases.

Twenty-three cases involved a shortage of antineoplastic agents, of which four cases were fatal. No inefficiency was reported.

Eighteen cases involved an antibiotic shortage with a majority of cutaneous disorders. No inefficiency was reported.

Sixteen cases involved anti-Parkinson's drugs with an ADR due to the replacement drug in 75% of the cases and inefficiency in 25% of the cases.

3.4 | Death and life-threatening situation cases in the context of drug shortage

Nine deaths and 18 life-threatening situations were observed. In half of these cases, no other aetiology was reported.

Four cases of death were related to medication errors. Two deaths occurred in the context of lomustine shortage due to packaging differences between the drug in shortage (four tablets) and the replacement drug (20 tablets) resulting in lomustine overdosage. One death occurred in the context of scopolamine shortage resulting in scopolamine overdosage and one death occurred in the context of metformin shortage resulting in lactic acidosis. Toxicity of the replacement drug without medication error was involved in four cases with a fatal outcome. Nadolol ($n = 1$), carmustine ($n = 1$), paclitaxel ($n = 1$) and danaparoid ($n = 1$) shortages resulted in cardiac arrest, Lyell's syndrome, aplasia and haemorrhagic complications, respectively. Worsening of the disease in the context of levodopa and levodopa-benserazide shortage was observed in one case of death.

Among the 18 cases involving life-threatening situations, the link between drug shortage and the clinical presentation was considered as certain in eight cases: dexchlorpheniramine replaced by promethazine ($n = 2$), imiglucerase replaced by taliglucerase ($n = 1$), amoxicillin clavulanic acid replaced by vancomycin ($n = 1$), alimemazine replaced by oxazepam ($n = 1$), calcium chloride replaced by calcium gluconate ($n = 1$), danaparoid replaced by lepirudin ($n = 1$) and enoxaparin replaced by fondaparinux ($n = 1$). Three cases of life-threatening situations were related to a medication error in the context of a dexchlorpheniramine shortage, phenytoin shortage and metformin shortage. Disease worsening was observed in two cases related to adenosine and mexiletine shortages.

4 | DISCUSSION

This study emphasized the increasing issue of ADR in the context of drug shortage over time. A large number of drug classes were concerned. The number of cases related to drug shortage increased much faster over time than the total number of pharmacovigilance cases included in the FPVB. The consequences of the replacement of the drugs in shortage were mainly represented by ADR, medication errors with or without ADRs and drug inefficiency, with 6% of cases with fatal outcomes and life-threatening situations.

The increasing number of cases reported has to be put into perspective with the increasing number of drug shortages reported by the health authorities.¹⁰ The French National Agency for the Safety of Medicines and Health Products (ANSM) reported 3530 pharmaceutical products in shortage between 2012 and 2018.¹⁰ The number of reported shortages increased between 2012 ($n = 200$) and 2018 ($n = 917$) with a sharp rise in 2017 and 2018.¹⁰ This evolution profile is close to the one observed in our study. The increasing number of drug shortages over time is also reported in many other countries. In a survey conducted by the European Association of Hospital Pharmacists (EAHP), 90% of the 1666 respondents within 38 countries claimed that shortage of medicines is a current problem in their institution.¹¹ This issue currently affects most countries worldwide, regardless of the country's income level.²

Most of the drug classes are represented in the included cases with a predominance of drugs for the nervous system, cardiovascular system and anti-infectives for systemic use. There are no discrepancies between the pharmacodynamic properties of the drugs classes predominately affected by drug shortage and the nature of suspected ADR reported. The distribution between ATC classes is similar to that identified in the ANSM report¹⁰ but slightly different to reports from other countries. Indeed, a survey conducted by the EAHP in 2018 also highlighted the predominance of antimicrobial agents, followed by oncology medicines, vaccines, anaesthetics and cardiovascular medicines¹² in this context. Another survey conducted by the AHA (American Hospital Association) on 820 non-federal, short-term acute care hospitals also identified, in addition to anti-infective and cardiovascular drugs, drugs used for anaesthesia, emergency care, gastrointestinal nutrition and pain management.¹³ Globally, essential medicine and emergency medicine appear to be more at risk of shortage than other medicines.^{2,14}

There are numerous consequences of drug shortages. This study examined drug shortage based on the reports transmitted to the pharmacovigilance network. Eleven per cent of the included cases were related to a medication error. A drug shortage may lead to a replacement of the unavailable product by an alternative. However, this alternative may have different packaging, labelling, dosage and sometimes a different route of administration that may increase the risk of a medication error.¹⁴ The medication errors reported here involved the administration step and were mainly related to human factors. In the literature, drug replacement in the context of drug shortage is widely identified as a risk factor of medication error.^{2,14} In a survey conducted by the Institute for Safe Medication Practices in the

United States, the authors considered that one in four actual errors and one in five reported adverse patient outcomes were due to drug shortage.¹⁵ The 2018 EHAP survey reported that 25% of medication errors were a consequence of drug shortages. In terms of oncology drug shortages, a survey distributed to 1672 members of the Haematology/Oncology Pharmacy Association revealed that 16% of the participants reported changes in therapy in the context of drug shortage that led to near-miss errors and 6% to medication errors.¹⁶

The reported adverse effects in the context of drug shortage are mainly due to the replacement drug. The clinical consequences are serious and lead to life-threatening situations or fatal outcomes in 6% of the cases included. Among these cases, two were related to an overdose due to a medication error in the context of a belustine shortage that led to a replacement with lomustine 40 mg. It is worth noting that antineoplastic drugs are particularly represented in fatal or life-threatening cases.

The main reported ADRs were related to nervous system disorders, which is in line with the number of cases involving nervous system drugs, with antiepileptic drugs being the most represented drugs. These drugs with a narrow therapeutic index have a high risk of toxicity or inefficiency in a context of drug replacement. Our study reported 18 cases related to phenytoin shortage. The drug was replaced by a formulation containing phenytoin sodium in 14 of these cases. The drug replacement resulted in seizure crises in ten cases due to the lack of bioequivalence, the pharmacokinetic profile of phenytoin characterized by a non-linear elimination depending on the concentration and the narrow therapeutic index.¹⁷ Prescribing promethazine as a replacement for dexchlorpheniramine or metoclopramide was also found in 34 cases. This resulted in the occurrence of an anticholinergic syndrome related to the pharmacodynamic properties of this drug: a neuroleptic antihistaminic H1 with a sedative, anticholinergic, peripheral alpha-blocking effect and antidopaminergic. Regarding the 18 cases involving antineoplastic drug shortage, without medication error, various specialities were involved, including mitomycin C, carmustine and caryolysin. Four cases were fatal in a context of aplasia. In the literature, the clinical impact of oncology drug shortages on patients has been poorly evaluated. In a survey, physicians reported a 35% increased risk of the alternative therapy.¹⁸

Drug replacement in the context of drug shortage may also have consequences in terms of efficacy, as reported in the present study. In the 67 cases affected by inefficiency, the most commonly involved drugs were antithrombotic agents, agents acting on the renin-angiotensin system and antiepileptics. The reported ADRs were directly related to the pharmacodynamic action of the drugs, such as thrombotic events, hypertension and seizures. Inefficiency is poorly identified by the pharmacovigilance system, as its main purpose is to collect data on ADRs.

In the literature, some published data suggest that drug shortage may impact patient's prognosis in terms of efficacy. A delay in the induction therapy of acute myeloid leukaemia has been reported in the context of cytarabine shortage.^{19,20} A report from the Children's Oncology Group showed that asparaginase discontinuation in the context of toxicity was associated with inferior disease-free survival

in high-risk patients, thus suggesting similar consequences in the context of drug shortage.²¹ For the treatment of bladder cancer, differences in efficacy were observed between two BCG strains in both a large retrospective study²² and in a randomized trial. These findings may have clinical consequences in the context of BCG shortages.²³ Antiretroviral drug shortage leading to a therapy interruption has been associated with an accumulation of drug mutations and an increased risk of treatment failure.⁹ A large retrospective study conducted in 26 US hospitals showed that mortality in patients admitted for septic shock was higher during the period of norepinephrine shortage.²⁴ Lastly, opioid shortage has been associated with a lower level of clinically improved pain in 386 patients treated for cancers.²⁵ All of these findings suggest that the consequences of drug shortage can affect both the efficacy and medication risk of ADRs.

The results of the study together with the published data raise the question of optimal drug replacement and the need for detailed information accompanying the replacement drug. In order to limit ADR and ME in the context of drug shortage, particular attention should be given to changes in packaging, dosage and drug interactions. The numerous ADRs identified in this study related to antiepileptic drugs highlight the precautions that should be taken with drugs with a narrow therapeutic index. Such precautions may include precise and comprehensive information provided to patients and health-care professionals regarding dosage and surveillance. At the level of the health authorities, ensuring the availability of essential drugs is crucial and may require the publication of essential medicine lists. In addition, safety issues regarding replacement drugs should also be considered, particularly when the choice is limited.

4.1 | Strengths and limitations of this study

The French pharmacovigilance system involves a network of pharmacovigilance centres covering the French territory. The ADR notifications provided by healthcare professionals and patients are accurately analysed by pharmacovigilance experts, and medical information is carefully collected, leading to the creation of a high-quality dataset. However, the adverse effects related to drug shortages presented in this study are probably underestimated due to the under-reporting usually observed in pharmacovigilance (estimated to be close to 10%). In addition, drug inefficiency is poorly identified by the pharmacovigilance system whose main objective is to collect ADRs. Further cohort studies are necessary to evaluate this point accurately.

5 | CONCLUSION

With the limits of the pharmacovigilance data, which are based on the patients and health care professional reports, this study emphasizes the clinical impact of drug shortages in terms of ADRs, medication errors and inefficiency. Regarding drug shortage safety issues, both drug in shortage and the replacement drug have to be taken into consideration. These observations support the position statements from

pharmacists and the health authorities about the need for health policy to limit the occurrence of drug shortages and to reinforce the information provided to patients and health care professionals in the context of drug shortage in order to limit the risk of medication errors.

ACKNOWLEDGEMENTS

The authors would like to thank the CHU d'Angers for its funding support (AOI 2020) and the French Network of Regional Pharmacovigilance Centres (RFCPRV).

COMPETING INTERESTS

The authors declare no conflicts of interest.

CONTRIBUTORS

M.B., D.B.M., M.Ba., L.L. conceived the idea for the study. D.B.M., C.M., M.Ba., G.D., A.G., H.G., M.L.L. curated the data. A.S., M.C., F.S. conducted the statistical analysis. D.B.M. acquired the funding. M.B., D.B.M., F.S. were responsible for the methodology. D.B.M., M. Ba., A.G., F.S., A.F., C.D.C., T.P., G.D., H.G., M.L.L., L.L. provided the resources. M.B., D.B.M., C.M., A.G., F.S., M.L.L. wrote the original draft. D.B.M., M.B., A.S., M.C., A.F., C.D.C., T.P., G.D., H.G., L.L. reviewed and edited the original draft.

DATA AVAILABILITY STATEMENT

The data presented in this study are available on request from the corresponding author. The request should be accompanied by a research protocol. The data are not publicly available due to European ethical and legal restrictions.

ORCID

Aurélie Grandvullemin  <https://orcid.org/0000-0001-6809-6975>

Francesco Salvo  <https://orcid.org/0000-0003-3210-7171>

Audrey Fresse  <https://orcid.org/0000-0001-7876-9846>

Marie-Laure Laroche  <https://orcid.org/0000-0003-4344-0359>

Marie Briet  <https://orcid.org/0000-0003-3738-5998>

REFERENCES

1. Stolar MH. Drug shortages. *Science*. 1976;192(4235):94. doi:10.1126/science.192.4235.94.a
2. Shukar S, Zahoor F, Hayat K, et al. Drug shortage: causes, impact, and mitigation strategies. *Front Pharmacol*. 2021;12:693426. doi:10.3389/fphar.2021.693426
3. Poulsen JH, Nørgaard LS, Dieckmann P, Clemmensen MH. Time spent by hospital personnel on drug changes: a time and motion study from an in- and outpatient hospital setting. *PLoS ONE*. 2021;16(2):e0247499. doi:10.1371/journal.pone.0247499
4. Cherif Chefchaoui A, Moutaouakkil Y, Adouani B, Tadlaoui Y, Lamsaouri J, Bousliman Y. Impact of anti-cancer drugs shortages in oncology and hematology departments in a Moroccan hospital. *J Oncol Pharm Pract*. 2022;28(4):822-826. doi:10.1177/10781552211008212
5. Messinger YH, Maxa KL, Hennen EM, Gossai NP, Hoff DS. Intrathecal methotrexate containing the preservative benzyl alcohol erroneously administered in pediatric leukemia patients: clinical course and preventive process. *J Pediatr Pharmacol Ther*. 2020;25(4):328-331. doi:10.5863/1551-6776-25.4.328

6. Kosarek L, Hart SR, Schultz L, Digiovanni N. Increase in venous complications associated with etomidate use during a propofol shortage: an example of clinically important adverse effects related to drug substitution. *Ochsner J*. 2011;11(2):143-146.
7. de Oliveira GS, Theilken LS, McCarthy RJ. Shortage of perioperative drugs: implications for anesthesia practice and patient safety. *Anesth Analg*. 2011;113(6):1429-1435. doi:10.1213/ANE.0b013e31821f23ef
8. Golembiewski J. Drug shortages in the perioperative setting: causes, impact, and strategies. *J Perianesth Nurs*. 2012;27(4):286-292. doi:10.1016/j.jopan.2012.05.005
9. Meloni ST, Chaplin B, Idoko J, et al. Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program. *AIDS Res Ther*. 2017;14(1):58. doi:10.1186/s12981-017-0184-5
10. Benhabib A, loughlissen S, Ratignier-Carbonneil C, Maison P. The French reporting system for drug shortages: description and trends from 2012 to 2018: an observational retrospective study. *BMJ Open*. 2020;10(3):e034033. doi:10.1136/bmjopen-2019-034033
11. EAHP. EAHP's 2018 survey on medicines shortages to improve patient outcomes [Internet]. www.eahp.eu/sites/default/files/report_medicines_shortages2018.pdf. Accessed April 29, 2022.
12. Miljković N, Gibbons N, Batista A, Fitzpatrick RW, Underhill J, Horák P. Results of EAHP's 2018 survey on medicines shortages. *Eur J Hosp Pharm*. 2019;26(2):60-65. doi:10.1136/ejpharm-2018-001835
13. American Hospital Association. AHA survey on drug shortages [Internet]. www.aha.org/system/files/content/11/drugshortagesurvey.pdf. Accessed April 29, 2022.
14. Dill S, Ahn J. Drug shortages in developed countries—reasons, therapeutic consequences, and handling. *Eur J Clin Pharmacol*. 2014;70(12):1405-1412. doi:10.1007/s00228-014-1747-1
15. Institute for Safe Medication Practices. Drug shortages: national survey reveals high level of frustration, low level of safety [Internet]. www.ismp.org/resources/special-issue-drug-shortages-national-survey-reveals-high-level-frustration-low-level. Accessed October 8, 2022.
16. McBride A, Holle LM, Westendorf C, et al. National survey on the effect of oncology drug shortages on cancer care. *Am J Health Syst Pharm*. 2013;70(7):609-617. doi:10.2146/ajhp120563
17. Auffret M, Tyvaert L, Laroche ML, et al. Drug shortage may have serious outcome: the French exemple of phenytoine. *Therapie*. 2015;70(4):377-380. doi:10.2515/therapie/2015018
18. Becker DJ, Talwar S, Levy BP, et al. Impact of oncology drug shortages on patient therapy: unplanned treatment changes. *J Oncol Pract*. 2013;9(4):e122-e128. doi:10.1200/JOP.2012.000799
19. Hedlund NG, Isgor Z, Zwanziger J, et al. Drug shortage impacts patient receipt of induction treatment. *Health Serv Res*. 2018;53(6):5078-5105. doi:10.1111/1475-6773.13028
20. Goldsack JC, Reilly C, Bush C, et al. Impact of shortages of injectable oncology drugs on patient care. *Am J Health Syst Pharm*. 2014;71(7):571-578. doi:10.2146/ajhp130569
21. Gupta S, Wang C, Raetz EA, et al. Impact of asparaginase discontinuation on outcome in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Clin Oncol*. 2020;38(17):1897-1905. doi:10.1200/JCO.19.03024
22. Witjes JA, Dalbagni G, Karnes RJ, et al. The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer. *Urol Oncol*. 2016;34(11):484.e19-484.e25. doi:10.1016/j.urolonc.2016.05.033
23. Rentsch CA, Birkhäuser FD, Biot C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. *Eur Urol*. 2014;66(4):677-688. doi:10.1016/j.eururo.2014.02.061
24. Vail E, Gershengorn HB, Hua M, Walkey AJ, Rubinfeld G, Wunsch H. Association between US norepinephrine shortage and mortality among patients with septic shock. *JAMA*. 2017;317(14):1433-1442. doi:10.1001/jama.2017.2841
25. Haider A, Qian Y, Lu Z, et al. Implications of the parenteral opioid shortage for prescription patterns and pain control among hospitalized patients with cancer referred to palliative care. *JAMA Oncol*. 2019;5(6):841-846. doi:10.1001/jamaoncol.2019.0062

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Bourneau-Martin D, Babin M, Grandvullemin A, et al. Adverse drug reaction related to drug shortage: A retrospective study on the French National Pharmacovigilance Database. *Br J Clin Pharmacol*. 2022;1-9. doi:10.1111/bcp.15550